Skip to main content

Peer Review reports

From: Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

Original Submission
2 Nov 2017 Submitted Original manuscript
22 Nov 2017 Reviewed Reviewer Report - Singal AK
26 Jan 2018 Author responded Author comments - Bjørn Madsen
Resubmission - Version 2
26 Jan 2018 Submitted Manuscript version 2
4 Feb 2018 Reviewed Reviewer Report - Singal AK
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
4 Feb 2018 Editorially accepted
26 Feb 2018 Article published 10.1186/s13063-018-2523-9

You can find further information about peer review here.

Back to article page